HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents

HemOnc Today honors inaugural Next Gen Innovators

Net neutrality repeal may diminish telemedicine access, harm small practices

Addition of daratumumab to chemotherapy doubles PFS in transplant-ineligible newly diagnosed myeloma

Cover Story

Pipeline of novel immunotherapies may offer ‘more nuanced approach’ to cancer treatment


Putting the CAR Ts before the horse

John Sweetenham, MD

FDA News

FDA grants fast track designation to gilteritinib for acute myeloid leukemia

FDA authorizes IMPACT test to rapidly identify cancer mutations

FDA approves Faslodex in combination with Verzenio for advanced breast cancer

FDA grants breakthrough therapy designation to BCMA antibody-drug conjugate for multiple myeloma

In the Journals Plus

Childhood cancer survivors more likely to stay at jobs for health insurance

Many cancers associated with modifiable risk factors

Prevalence of secondary cancers underscores need for trial inclusion

Melanoma immunotherapy trials may not capture all toxicity data

Meeting News

Ibrutinib plus venetoclax shows promise for chronic lymphocytic leukemia

SRP54 discovered as a novel cause of congenital neutropenia

Responses with CAR T-cell therapy appear durable for non-Hodgkin lymphoma

Pembrolizumab combination shows early potential for trastuzumab-resistant breast cancer

High-throughput sequencing aids in diagnosis of bleeding, platelet disorders

Exemestane continues to improve DFS, not OS, for early breast cancer

Exemestane plus enzalutamide extends PFS in some women with breast cancer

Combined score enhances understanding of breast cancer risk

Acupuncture reduces joint pain during treatment for early-stage breast cancer

Circulating tumor cells predict risk for late breast cancer recurrence

Graft failure remains concern following umbilical cord blood transplantation for leukemia

Extended bisphosphonate treatment fails to improve breast cancer survival

Trastuzumab fails to improve outcomes for HER-2-low breast cancer


Is the success of future immunotherapies dependent on biomarkers?